Modifier and HCPCS Changes for October 2024

The following new and deleted National Level II modifiers and Healthcare Common Procedure Coding System (HCPCS) are effective for dates of service on/after October 1, 2024.

In compliance with the Health Insurance Portability and Accountability Act (HIPAA), CMS eliminated the 3-month grace period for discontinued codes in Change Request (CR) 3093 dated February 6, 2004. Effective for dates of services on/after January 1, 2010, there is no grace period for billing discontinued HCPCS codes.

Note: The inclusion of modifiers or codes on this web page do not necessarily indicate coverage. New modifiers and HCPCS identified as Durable Medical Equipment (DME) are not included in this listing.

 

New Modifiers

There are no new modifiers being implemented.

New Codes

HCPCS DESCRIPTION
A2027 Matriderm, per square centimeter
A2028 Micromatrix flex, per mg
A2029 Mirotract wound matrix sheet, per cubic centimeter
A9610 Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
C8000 Support device, extravascular, for arteriovenous fistula (implantable)
C9169 Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
C9170 Injection, tarlatamab-dlle, 1 mg
C9171 Injection, pegulicianine, 1 mg
C9172 Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
J0138 Injection, acetaminophen 10 mg and ibuprofen 3 mg
J1171 Injection, hydromorphone, 0.1 mg
J1749 Injection, iloprost, 0.1 mcg
J2002 Injection, lidocaine hcl in 5% dextrose, 1 mg
J2003 Injection, lidocaine hydrochloride, 1 mg
J2004 Injection, lidocaine hcl with epinephrine, 1 mg
J2252 Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
J2253 Injection, midazolam (seizalam), 1 mg
J2601 Injection, vasopressin (baxter), 1 unit
J8522 Capecitabine, oral, 50 mg
J8541 Dexamethasone (hemady), oral, 0.25 mg
J9329 Injection, tislelizumab-jsgr, 1mg
P9027 Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit
Q0519 Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days
Q0520 Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days
Q4334 Amnioplast 1, per square centimeter
Q4335 Amnioplast 2, per square centimeter
Q4336 Artacent c, per square centimeter
Q4337 Artacent trident, per square centimeter
Q4338 Artacent velos, per square centimeter
Q4339 Artacent vericlen, per square centimeter
Q4340 Simpligraft, per square centimeter
Q4341 Simplimax, per square centimeter
Q4342 Theramend, per square centimeter
Q4343 Dermacyte ac matrix amniotic membrane allograft, per square centimeter
Q4344 Tri-membrane wrap, per square centimeter
Q4345 Matrix hd allograft dermis, per square centimeter
Q5135 Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Q5136 Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg

Deleted Codes

HCPCS DESCRIPTION
C9150 Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
J1170 Injection, hydromorphone, up to 4 mg
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg
J8520 Capecitabine, oral, 150 mg
J8521 Capecitabine, oral, 500 mg
J9258 Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg

Source

  • Transmittal 12655, CR 13575 dated May 23, 2024
Last Updated Sep 16 , 2024